CO2023004558A2 - Conjugados de anticuerpo-fármaco que comprenden peptidomiméticos glp1 y usos de los mismos - Google Patents
Conjugados de anticuerpo-fármaco que comprenden peptidomiméticos glp1 y usos de los mismosInfo
- Publication number
- CO2023004558A2 CO2023004558A2 CONC2023/0004558A CO2023004558A CO2023004558A2 CO 2023004558 A2 CO2023004558 A2 CO 2023004558A2 CO 2023004558 A CO2023004558 A CO 2023004558A CO 2023004558 A2 CO2023004558 A2 CO 2023004558A2
- Authority
- CO
- Colombia
- Prior art keywords
- glp1
- drug conjugates
- peptidomimetics
- antibody
- glp1r
- Prior art date
Links
- 239000000816 peptidomimetic Substances 0.000 title abstract 4
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 3
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 abstract 2
- 102100040918 Pro-glucagon Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000001990 protein-drug conjugate Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077983P | 2020-09-14 | 2020-09-14 | |
| PCT/US2021/050337 WO2022056494A1 (en) | 2020-09-14 | 2021-09-14 | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023004558A2 true CO2023004558A2 (es) | 2023-04-27 |
Family
ID=78080567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0004558A CO2023004558A2 (es) | 2020-09-14 | 2023-04-12 | Conjugados de anticuerpo-fármaco que comprenden peptidomiméticos glp1 y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12280124B2 (https=) |
| EP (1) | EP4210767A1 (https=) |
| JP (1) | JP2023542295A (https=) |
| KR (1) | KR20230070337A (https=) |
| CN (1) | CN116615251A (https=) |
| AU (1) | AU2021339892A1 (https=) |
| CA (1) | CA3191304A1 (https=) |
| CL (2) | CL2023000678A1 (https=) |
| CO (1) | CO2023004558A2 (https=) |
| IL (1) | IL301074A (https=) |
| MX (1) | MX2023002974A (https=) |
| WO (1) | WO2022056494A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3191304A1 (en) | 2020-09-14 | 2022-03-17 | Amy Han | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
| JP2025512735A (ja) | 2022-03-11 | 2025-04-22 | リジェネロン ファーマシューティカルズ，インク． | Ｇｌｐ１ペプチド模倣体を含む抗ｇｌｐ１ｒ抗体係留型薬物コンジュゲートおよびその使用 |
| WO2024027715A1 (en) * | 2022-08-01 | 2024-02-08 | Sciwind Biosciences Usa Co., Ltd | Anti-glp-1r antibodies and uses thereof |
| AU2024229138A1 (en) | 2023-02-27 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Liquid phase peptide support synthesis of peptides and peptidomimetics |
| US20250171516A1 (en) | 2023-11-03 | 2025-05-29 | Regeneron Pharmaceuticals, Inc. | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof |
| TW202535467A (zh) * | 2023-12-29 | 2025-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗體－多肽偶聯物及其醫藥用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| CA2707448C (en) * | 2007-12-11 | 2014-10-14 | Cadila Healthcare Limited | Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| AU2009275358C1 (en) | 2008-07-21 | 2015-09-24 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| FR2937972B1 (fr) | 2008-11-04 | 2013-03-29 | Galderma Res & Dev | Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| KR101000067B1 (ko) | 2008-12-30 | 2010-12-10 | 엘지전자 주식회사 | 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법 |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| WO2011048614A2 (en) * | 2009-10-22 | 2011-04-28 | Cadila Healthcare Limited | Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist |
| SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| SMT201700023T1 (it) | 2010-08-02 | 2017-03-08 | Regeneron Pharma | Topi che producono proteine leganti vl |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| CN110078789A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| RU2014124984A (ru) | 2011-12-05 | 2016-01-27 | Идженика Биотерапьютикс, Инк. | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| US9911931B2 (en) | 2014-06-26 | 2018-03-06 | Universal Display Corporation | Organic electroluminescent materials and devices |
| GB2551945B (en) * | 2015-12-18 | 2021-09-08 | Heptares Therapeutics Ltd | Novel GLP-1 receptor agonist peptides |
| BR112018014759B1 (pt) | 2016-01-25 | 2024-02-27 | Regeneron Pharmaceuticals, Inc | Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso |
| EP3419670A2 (en) | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| IL313587A (en) * | 2017-01-17 | 2024-08-01 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| JP7702428B2 (ja) | 2020-05-12 | 2025-07-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｇｌｐ１ｒアンタゴニスト抗体およびその使用方法 |
| CA3191304A1 (en) | 2020-09-14 | 2022-03-17 | Amy Han | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
-
2021
- 2021-09-14 CA CA3191304A patent/CA3191304A1/en active Pending
- 2021-09-14 EP EP21787235.7A patent/EP4210767A1/en active Pending
- 2021-09-14 WO PCT/US2021/050337 patent/WO2022056494A1/en not_active Ceased
- 2021-09-14 IL IL301074A patent/IL301074A/en unknown
- 2021-09-14 KR KR1020237012710A patent/KR20230070337A/ko active Pending
- 2021-09-14 JP JP2023516467A patent/JP2023542295A/ja active Pending
- 2021-09-14 CN CN202180076678.6A patent/CN116615251A/zh active Pending
- 2021-09-14 AU AU2021339892A patent/AU2021339892A1/en active Pending
- 2021-09-14 US US17/475,248 patent/US12280124B2/en active Active
- 2021-09-14 MX MX2023002974A patent/MX2023002974A/es unknown
-
2023
- 2023-03-09 CL CL2023000678A patent/CL2023000678A1/es unknown
- 2023-04-12 CO CONC2023/0004558A patent/CO2023004558A2/es unknown
-
2025
- 2025-01-16 US US19/023,874 patent/US20250161476A1/en active Pending
- 2025-08-21 CL CL2025002511A patent/CL2025002511A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023002974A (es) | 2023-05-25 |
| AU2021339892A1 (en) | 2023-04-27 |
| IL301074A (en) | 2023-05-01 |
| CL2023000678A1 (es) | 2023-10-20 |
| CN116615251A (zh) | 2023-08-18 |
| AU2021339892A9 (en) | 2024-02-08 |
| US20250161476A1 (en) | 2025-05-22 |
| US12280124B2 (en) | 2025-04-22 |
| JP2023542295A (ja) | 2023-10-06 |
| EP4210767A1 (en) | 2023-07-19 |
| WO2022056494A1 (en) | 2022-03-17 |
| KR20230070337A (ko) | 2023-05-22 |
| CA3191304A1 (en) | 2022-03-17 |
| US20220096648A1 (en) | 2022-03-31 |
| CL2025002511A1 (es) | 2025-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023004558A2 (es) | Conjugados de anticuerpo-fármaco que comprenden peptidomiméticos glp1 y usos de los mismos | |
| CL2024003681A1 (es) | Conjugado de anticuerpo anti-b7h3-fármaco y uso del mismo | |
| CO2021016552A2 (es) | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso | |
| BR112019022495A2 (pt) | Conjugados de anticorpo que compreendem agonista de receptor similar a toll e terapias de combinação | |
| MX2022015399A (es) | Conjugados de superficie celular y composiciones y metodos celulares relacionados. | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| NZ742916A (en) | C-terminal lysine conjugated immunoglobulins | |
| PE20090245A1 (es) | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos | |
| MX2020010408A (es) | Conjugados de anticuerpo-farmaco y sus usos para el tratamiento del cancer. | |
| PE20120514A1 (es) | Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica | |
| CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso | |
| CO2025000513A2 (es) | Anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1, composiciones que comprenden anticuerpos anti-ror1 o conjugados de anticuerpos anti-ror1 y métodos para hacer y usar anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1 | |
| BR112021015477A2 (pt) | Anticorpos anti-cd228 e conjugados anticorpo-fármaco | |
| CL2022001196A1 (es) | Conjugados anticuerpo-fármaco dirigidos a la claudina 18.2 | |
| MX2023015101A (es) | Polipeptidos que se dirigen a canceres cd70-positivos. | |
| MX2024011099A (es) | Conjugados de farmaco unido a anticuerpo anti-glp1r que comprenden peptidomimeticos de glp1 y usos de los mismos. | |
| ECSP20020949A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos | |
| CO2025008047A2 (es) | Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos | |
| BR112022013255A2 (pt) | Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo | |
| MX2022014231A (es) | Conjugados de anticuerpo-farmaco que se enfocan a la uparap. | |
| CO2025004991A2 (es) | Anticuerpo anti-gucy2c y usos del mismo | |
| CO2025002048A2 (es) | Anticuerpos anti monometil auristatina y fragmentos de anticuerpos | |
| CL2025002572A1 (es) | Anticuerpo anti-5t4; composición farmacéutica que lo comprende; y su uso. | |
| PE20252772A1 (es) | Anticuerpo que se une al dominio similar a la proteasa del receptor de transferrina humano htfr1 |